CRIS

Curis Inc

Add to Watchlist

Advanced Chart

1.670

+0.02(1.212%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.740

Open

1.680

VWAP

1.67

Vol

30.37K

Mkt Cap

20.87M

Low

1.640

Amount

50.59K

EV/EBITDA(TTM)

Total Shares

5.89M

10.49M

EV/OCF(TTM)

P/S(TTM)

1.26

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

2.86M

-2.42%

-0.600

-64.71%

3.03M

-9.32%

-0.463

-58.33%

3.20M

+34.45%

-0.390

-68.8%

Estimates Revision

The market is revising Upward the revenue expectations for Curis, Inc. (CRIS) for FY2025, with the revenue forecasts being adjusted by 3.29% over the past three months. During the same period, the stock price has changed by -18.14%.

Revenue Estimates for FY2025

Revise Upward

+3.29%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-32.6%

In Past 3 Month

Stock Price

Go Down

-18.14%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast CRIS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRIS is 14.50 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.670

Low

12.00

Averages

14.50

High

17.00

Current: 1.670

Low

12.00

Averages

14.50

High

17.00

H.C. Wainwright

Buy

initiated

$17

2025-05-19

Reason

H.C. Wainwright

Price Target

$17

2025-05-19

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Curis with a Buy rating and $17 price target. Curis is a clinical-stage biopharmaceutical company developing novel therapies for cancer treatment, the analyst tells investors in a research note. The firm says the company's lead drug candidate, emavusertib, is a potential first-in-class oral, small molecule inhibitor of IRAK4, which mediates signaling downstream of toll-like receptor superfamily. It sees a "promising" early efficacy profile in the lead non-Hodgkin's lymphoma subtype being evaluated in TakeAim lymphoma.

HC Wainwright & Co.

Edward White

Strong Buy

Maintains

$20 → $16

2025-03-31

Reason

HC Wainwright & Co.

Edward White

Price Target

$20 → $16

2025-03-31

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

$20

2024-12-10

Reason

HC Wainwright & Co.

Edward White

Price Target

$20

2024-12-10

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

$20

2024-11-15

Reason

HC Wainwright & Co.

Edward White

Price Target

$20

2024-11-15

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Edward White

Strong Buy

Maintains

$26 → $20

2024-11-01

Reason

HC Wainwright & Co.

Edward White

Price Target

$26 → $20

2024-11-01

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

$26

2024-09-27

Reason

HC Wainwright & Co.

Edward White

Price Target

$26

2024-09-27

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Curis Inc (CRIS.O) is -0.96, compared to its 5-year average forward P/E of -5.19. For a more detailed relative valuation and DCF analysis to assess Curis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.19

Current PE

-0.96

Overvalued PE

2.08

Undervalued PE

-12.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.95

Current EV/EBITDA

-1.00

Overvalued EV/EBITDA

2.49

Undervalued EV/EBITDA

-8.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

21.13

Current PS

1.72

Overvalued PS

50.68

Undervalued PS

-8.42